How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

β-L-Hydroxycytosin – a novel class of Nucleoside Analogue Reverse Transcriptase Inhibitors for the Treatment of Hepatitis B Viral Infections

Organization name

ascenion GmbH

Profile

Challenge

Today more than 350 million people are infected with the Hepatitis B virus (HBV) throughout the world. Despite established vaccine strategies, the global challenge of the chronic disease is still alive, in particular considering quick development of resistance strains and  novel effective HBV drugs are still required.

Technology

b-L-Hydroxycytosin nucleotide derivatives are a novel compound class of nucleoside analogue reverse transcriptase inhibitors (NRTI) for the treatment of HBV infection with extremely low cytotoxicity compared to known HBV drugs. In cellular assays, the compounds show up to three-fold lower IC50 values than the HBV drug Lamivudin. Cellular, including mitochondrial, polymerases, are significantly less sensitive to the compounds (>>70µM), demonstrating HBV Polymerase selectivity. Only a very low mutagenity was detectable in a mini-AMES assay. First in vivo experiments also indicate no cytotoxic side effect of the substances, making them promising candidates for the development of anti-HBV drugs and broadening the compound portfolio for HBV combination therapy.

Commercial Opportunity

Exclusive in-licensing opportunity for the development of a HBV drug.

Developmental Status

Pre-clinical in vitro proof of concept in biochemical and cellular assays. Initial confidential in vivo results available.

Patent Situation

Patent applications based on WO 2006/045616 are pending in Europe and USA.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries